EMIS.OB -- 2 x PIII Studien mit Novartis !!! - 500 Beiträge pro Seite
eröffnet am 05.09.09 14:07:31 von
neuester Beitrag 09.09.11 11:21:36 von
neuester Beitrag 09.09.11 11:21:36 von
Beiträge: 47
ID: 1.152.844
ID: 1.152.844
Aufrufe heute: 0
Gesamt: 4.403
Gesamt: 4.403
Aktive User: 0
ISIN: US2913451066 · WKN: 882963
7,8100
USD
+0,13 %
+0,0100 USD
Letzter Kurs 09.12.20 Nasdaq OTC
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2000 | +471,16 | |
| 0,8800 | +57,14 | |
| 13,110 | +38,44 | |
| 0,8900 | +27,14 | |
| 1,7400 | +24,29 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,150 | -19,76 | |
| 36,70 | -22,87 | |
| 1,3500 | -26,63 | |
| 14,890 | -27,19 | |
| 2,7280 | -29,14 |
Feedback
Ich wollte mich nochmal bedanken an alle die mir geschrieben haben !!!
-------------------------------------------------------------------
Diese Aktie könnte ein Knaller werden !!!!!!!!!!
Emisphere hat 2 Phase III Studien (osteoarthritis und osteoporosis) mit Novartis am laufen .
Die Patientenrekrutierung für Osteoarthritis in der PIII-Zulassungsstudie ist bereits abgeschlossen .
Bin gestern mit erstmal 5000st eingestiegen .
Muss los in den nächsten Tagen folgt mehr ..
Emisphere (EMIS.OB)
Marktkap: 31 M$
Cash : 9 Mio$ << reicht für 1 Jahr
Kurs: 0,85 $
Direktor kauft über 6 Mio Aktien !!!!
http://finance.yahoo.com/q/it?s=EMIS.OB
Pipeline :
http://www.emisphere.com/stages_product_development.html
Top Shareholder
http://ir.emisphere.com/ownership-profile.cfm
KEY PRODUCT AND CORPORATE DEVELOPMENTS
* On July 28, 2009, Emisphere announced that, concurrent with the publication of two papers in the July/August issue of the peer reviewed journal, International Journal of Toxicology, which describes the toxicology of its Sodium N-[8-(2-hydroxybenzoyl) Amino] Caprylate ("SNAC") carrier, SNAC has achieved Generally Recognized as Safe ("GRAS") status for its intended application in combination with nutrients added to food and dietary supplements. After a comprehensive evaluation of research and toxicology data, SNAC was found to be safe at a dosage of up to 250 mg per day when used in combination with nutrients to improve their dietary availability. With GRAS status, the SNAC carrier is exempt from pre-market approval and management can move ahead with plans to commercialize its first product, a low dose (100 mcg) Over-The-Counter ("OTC"), oral Eligen(R) Vitamin B12.
* On June 22, 2009, the Company entered into a research agreement to combine Emisphere's proprietary Eligen(R) oral drug delivery technology with a new oral drug delivery system developed in the laboratory of Robert Doyle, Assistant Professor of Chemistry in Syracuse University's College of Arts and Sciences. The research will evaluate whether the combination of Eligen(R) and Doyle's oral drug delivery technology will enhance the absorption of an appetite-suppressing hormone.
* On June 1, 2009, Emisphere announced that Novartis Pharma AG and Nordic Bioscience had completed recruitment for the planned second multi-center Phase III study exploring the safety and efficacy of an oral formulation of salmon calcitonin using Emisphere's proprietary Eligen(R) Technology to treat patients with osteoarthritis of the knee. This study, which is intended to be used to support a regulatory filing in the U.S., includes more than 900 patients between the ages of 51 and 80 with a medical history and symptoms of knee osteoarthritis. The two year study is being conducted in Europe, the U.S. and several other countries.
* On May 26, 2009, Emisphere reported encouraging data from a clinical study conducted at the University Hospital in Basel, Switzerland, assessing the effect of oral administration of two peptides, GLP-1 and PYY3-36, utilizing Emisphere's Eligen(R) Technology on appetite suppression. The study concluded that these orally administered peptides, when delivered with Emisphere's SNAC carrier, were rapidly absorbed from the gastrointestinal tract, leading to concentrations several times higher than endogenous hormone levels achieved after a standard test meal, resulting in a meaningful reduction in calorie intake.
Emisphere (NASDAQ:EMIS) is an emerging bio-pharma company specializing in the development of a drug delivery technology platform for the oral administration of therapeutic compounds which are either poorly absorbed or must be given through alternative routes such as injections.
On 6/1/09, EMIS announced that Novartis (NYSE:NVS) and Nordic Bioscience have completed recruitment for the planned second multi-center Phase 3 study exploring the safety and efficacy of an oral formulation of salmon calcitonin using Emisphere’s proprietary Eligen Technology to treat patients with osteoarthritis of the knee. This study, which is intended to be used to support a FDA regulatory approval filing in the U.S., includes more than 900 patients between the ages of 51-80 with a medical history and symptoms of knee osteoarthritis. The study is being conducted in Europe and the U.S., as well as other countries, and is a two year study.
Oral calcitonin is also being investigated using Eligen Technology in a Phase 3 study for osteoporosis. Both indications for the compound are in Phase 3 development with over 6,000 patients enrolled in three clinical studies. The osteoporosis trial is a three year trial initiated in February 2007 and the two year osteoarthritis trial beginning in May 2007 with the second two year trial for osteoarthritis initiated in June 2008.
On 5/26/09, EMIS announced data from a clinical study designed to assess the effect of oral administration of two peptides (GLP-1 and PYY3-36) utilizing Emisphere’s Eligen Technology on appetite suppression. The randomized, double-blind, placebo-controlled trial was conducted in 16 normal weight males between the ages of 18-40. The study concluded that these orally administered peptides, when delivered with Emisphere’s SNAC carrier, were rapidly absorbed from the gastrointestinal tract, leading to concentrations several times higher than endogenous hormone levels achieved after a standard test meal.
Specifically, results showed that oral GLP-1 (2 mg tablet) alone and the combination of oral GLP-1 (2 mg tablet) plus PYY3-36 (1 mg tablet) induced a significant reduction in calorie intake although there was no synergistic effect when the two peptides were used in combination. The data was encouraging and will warrant further investigation in clinical trials for appetite suppression and the results further validate the Company’s Eligen Technology and SNAC carrier’s ability to improve the oral absorption of peptides.
In June 2008, EMIS announced an exclusive deal with Novo Nordisk (NYSE:NVO) to develop and commercialize oral formulations of the latter’s proprietary GLP-1 receptor agonists for the potential treatment of Type 2 diabetes. Previously conducted clinical trials have confirmed that the Company’s SNAC drug delivery technology allows for the safe and rapid oral absorption of GLP-1.
On 5/21/09, EMIS received a $500,000 milestone payment from MannKind (NASDAQ:MNKD) in connection with that Company’s recent FDA filing and acceptance of a NDA for Afresa as an inhaled, ultra rapid-acting insulin. In early 2008, EMIS sold the rights to certain drug delivery patents to MNKD for an initial payment of $1.5M, and an additional payment of $500,000 remains to be paid to EMIS no later than 10/5/10.
In early May, EMIS reported 1Q09 financial results, which included a net loss of $5.1M and an operating loss of $4.7M compared to a net loss of $3.9M and an operating loss of $6.5M in the year-ago periods. Total operating expenses during 1Q09 were $4.7M versus $6.6M in the year-ago period. At the end of 1Q09, EMIS reported a cash/restricted cash balance of $4.2M, with sufficient capital resources through August 2009 as the Company evaluates both non-dilutive and traditional financing options. Additionally, EMIS achieved a key milestone as part of its cost cutting initiatives with a goal of reducing the Company’s cash burn rate to a level of $7-8M per year.
Another important milestone achieved in early May occurred when the Company was informed by an independent expert panel of scientists that its SNAC carrier was provisionally designated as Generally Recognized as Safe (GRAS) for its intended application in combination with nutrients added to food and dietary supplements. Following a comprehensive evaluation of research and toxicology data, Emisphere’s SNAC was found to be safe at a dosage up to 250 mg per day when used in combination with nutrients to improve their dietary availability.
Achieving final GRAS status will allow EMIS to bypass the FDA as it seeks to commercialize its drug delivery technology to improve the oral absorption of vitamins and other nutritional supplements, such as <font> the Company’s first target – vitamin B12 </font> . EMIS expects to achieve final GRAS status following the publication of two peer reviewed papers describing the toxicology of SNAC, currently scheduled for July/August in the International Journal of Toxicology .
A pharmacokinetic study conducted by EMIS demonstrated that mean vitamin B12 peak blood levels were more than 10X higher for the Eligen B12 5mg formulation compared to a 5mg commercial formulation. In addition, the Eligen formulation was absorbed much quicker as it reached a peak concentration in just 30 minutes versus 6.8 hours for the standard commercial formulation. The overall absorption of B12 was increased by about 240% for the Eligen formulation compared to the standard formulation.
On 4/1/09, Par Pharma (NYSE:PRX) announced that its wholly-owned subsidiary focused on the development of proprietary drug products, Strativa Pharma, acquired the global rights to Nascobal (Cyanocobalamin) Nasal Spray from QOL Medical, LLC. Nascobal Nasal Spray is an FDA approved prescription vitamin B12 supplement indicated to treat vitamin B12 deficiency, and the product represents the first and only once-weekly, self-administered alternative to B12 injections. Strativa Pharma paid $54.5M for the worldwide rights to Nascobal, which equates to nearly 7X the $8M in sales for the product during 2008.
Based on the PRX acquisition, EMIS would be undervalued at its current market cap around $35M based on the potential for an orally available, high-dose B12 product only. A prescription strength B12 formulation that could be taken by mouth would quickly become the market leader as patients would prefer this route to an injection or a squirt up the nose. Other near-term opportunities are possible for poorly absorbed and widely used mineral supplements such as iron.
Of course, EMIS has more than just the near-term opportunity for improved oral delivery of vitamins and nutritional supplements with three ongoing Phase 3 trials for oral calcitonin funded and being conducted by Novartis for the treatment of conditions with major commercial potential in osteoporosis and osteoarthritis. In addition, there is minimal risk of failure or toxicity in the trials since the effects of calcitonin are well characterized and EMIS is simply improving upon the delivery of the drug.
Outstanding issues weighing on the share price include the obvious need for some type of funding or financing by August, submitting additional information by 6/26/09 to maintain the Company’s NASDAQ listing, two outstanding notes, and litigation related to the proprietary technology for the oral administration of vitamin B12 against a former consultant/employee of EMIS. In February 2009, the defendants filed a countersuit against EMIS and the Company believes the counterclaims are without merit and plans to further litigate the matter.
Two outstanding notes payable include a $12.1M Novartis Note which matures on 12/1/09 and currently bears interest at a rate of 7%. EMIS may convert the Novartis Note at any time prior to maturity into a number of shares of its common stock equal to the principal, accrued, and unpaid interest to be converted divided by the then market price of our common stock, provided certain conditions are met. At the end of 1Q09, a portion of the Novartis Note was convertible into 7.54M shares of EMIS common stock.
Conditions affecting this note include that the number of shares issued to Novartis, when issued, does not exceed 19.9% of the total shares of the Company’s common stock outstanding, that at the time of such conversion no event of default under the Note has occurred and is continuing, and that there is either an effective shelf registration statement in effect covering the resale of the shares issued in connection with such conversion or the shares may be resold by Novartis pursuant to SEC Rule 144.
EMIS also has $18.85M in outstanding MHR Convertible Notes. The Convertible Notes are due on 9/26/12 and bear interest at 11% and are secured by a first priority lien in favor of MHR Institutional Partners on substantially all of the Company’s assets. Interest is payable in the form of additional Convertible Notes issued monthly through March 31, 2007 and then semi-annually beginning June 30, 2008, rather than in cash and we have the right to call the Convertible Notes after September 26, 2010 if certain conditions are satisfied.
Further the Convertible Notes provide MHR with the right to require redemption in the event of a change in control, as defined, prior to September 26, 2009. Such required redemption would be at 102% and 101% of the then outstanding principal and interest in the years through September 26, 2008 and 2009, respectively. The Convertible Notes are convertible, at the sole discretion of MHR or any assignee thereof through September 25, 2010, into shares of our common stock at a price per share of $3.78. At March 31, 2009, the Convertible Notes were convertible into 5.5M shares of EMIS common stock.
Despite the issues outlined above which are weighing on the current stock price, EMIS has a promising drug delivery with little in the way of pipeline risk for its Phase 3 oral calcitonin clinical trials since they involve the improved oral delivery of an already used hormone. In addition, the PRX acquisition at 7X sales ($54.5M) for a B12 nasal spray product is similar to the current enterprise value for EMIS ($60M). EMIS should be viewed as a call option trade at its current stock price just north of $1/share, with the potential for multi-bagger gains if the risk factors outlined above are resolved successfully.
-------------------------------------------------------------------
Diese Aktie könnte ein Knaller werden !!!!!!!!!!
Emisphere hat 2 Phase III Studien (osteoarthritis und osteoporosis) mit Novartis am laufen .
Die Patientenrekrutierung für Osteoarthritis in der PIII-Zulassungsstudie ist bereits abgeschlossen .
Bin gestern mit erstmal 5000st eingestiegen .
Muss los in den nächsten Tagen folgt mehr ..
Emisphere (EMIS.OB)
Marktkap: 31 M$
Cash : 9 Mio$ << reicht für 1 Jahr
Kurs: 0,85 $
Direktor kauft über 6 Mio Aktien !!!!
http://finance.yahoo.com/q/it?s=EMIS.OB
Pipeline :
http://www.emisphere.com/stages_product_development.html
Top Shareholder
http://ir.emisphere.com/ownership-profile.cfm
KEY PRODUCT AND CORPORATE DEVELOPMENTS
* On July 28, 2009, Emisphere announced that, concurrent with the publication of two papers in the July/August issue of the peer reviewed journal, International Journal of Toxicology, which describes the toxicology of its Sodium N-[8-(2-hydroxybenzoyl) Amino] Caprylate ("SNAC") carrier, SNAC has achieved Generally Recognized as Safe ("GRAS") status for its intended application in combination with nutrients added to food and dietary supplements. After a comprehensive evaluation of research and toxicology data, SNAC was found to be safe at a dosage of up to 250 mg per day when used in combination with nutrients to improve their dietary availability. With GRAS status, the SNAC carrier is exempt from pre-market approval and management can move ahead with plans to commercialize its first product, a low dose (100 mcg) Over-The-Counter ("OTC"), oral Eligen(R) Vitamin B12.
* On June 22, 2009, the Company entered into a research agreement to combine Emisphere's proprietary Eligen(R) oral drug delivery technology with a new oral drug delivery system developed in the laboratory of Robert Doyle, Assistant Professor of Chemistry in Syracuse University's College of Arts and Sciences. The research will evaluate whether the combination of Eligen(R) and Doyle's oral drug delivery technology will enhance the absorption of an appetite-suppressing hormone.
* On June 1, 2009, Emisphere announced that Novartis Pharma AG and Nordic Bioscience had completed recruitment for the planned second multi-center Phase III study exploring the safety and efficacy of an oral formulation of salmon calcitonin using Emisphere's proprietary Eligen(R) Technology to treat patients with osteoarthritis of the knee. This study, which is intended to be used to support a regulatory filing in the U.S., includes more than 900 patients between the ages of 51 and 80 with a medical history and symptoms of knee osteoarthritis. The two year study is being conducted in Europe, the U.S. and several other countries.
* On May 26, 2009, Emisphere reported encouraging data from a clinical study conducted at the University Hospital in Basel, Switzerland, assessing the effect of oral administration of two peptides, GLP-1 and PYY3-36, utilizing Emisphere's Eligen(R) Technology on appetite suppression. The study concluded that these orally administered peptides, when delivered with Emisphere's SNAC carrier, were rapidly absorbed from the gastrointestinal tract, leading to concentrations several times higher than endogenous hormone levels achieved after a standard test meal, resulting in a meaningful reduction in calorie intake.
Emisphere (NASDAQ:EMIS) is an emerging bio-pharma company specializing in the development of a drug delivery technology platform for the oral administration of therapeutic compounds which are either poorly absorbed or must be given through alternative routes such as injections.
On 6/1/09, EMIS announced that Novartis (NYSE:NVS) and Nordic Bioscience have completed recruitment for the planned second multi-center Phase 3 study exploring the safety and efficacy of an oral formulation of salmon calcitonin using Emisphere’s proprietary Eligen Technology to treat patients with osteoarthritis of the knee. This study, which is intended to be used to support a FDA regulatory approval filing in the U.S., includes more than 900 patients between the ages of 51-80 with a medical history and symptoms of knee osteoarthritis. The study is being conducted in Europe and the U.S., as well as other countries, and is a two year study.
Oral calcitonin is also being investigated using Eligen Technology in a Phase 3 study for osteoporosis. Both indications for the compound are in Phase 3 development with over 6,000 patients enrolled in three clinical studies. The osteoporosis trial is a three year trial initiated in February 2007 and the two year osteoarthritis trial beginning in May 2007 with the second two year trial for osteoarthritis initiated in June 2008.
On 5/26/09, EMIS announced data from a clinical study designed to assess the effect of oral administration of two peptides (GLP-1 and PYY3-36) utilizing Emisphere’s Eligen Technology on appetite suppression. The randomized, double-blind, placebo-controlled trial was conducted in 16 normal weight males between the ages of 18-40. The study concluded that these orally administered peptides, when delivered with Emisphere’s SNAC carrier, were rapidly absorbed from the gastrointestinal tract, leading to concentrations several times higher than endogenous hormone levels achieved after a standard test meal.
Specifically, results showed that oral GLP-1 (2 mg tablet) alone and the combination of oral GLP-1 (2 mg tablet) plus PYY3-36 (1 mg tablet) induced a significant reduction in calorie intake although there was no synergistic effect when the two peptides were used in combination. The data was encouraging and will warrant further investigation in clinical trials for appetite suppression and the results further validate the Company’s Eligen Technology and SNAC carrier’s ability to improve the oral absorption of peptides.
In June 2008, EMIS announced an exclusive deal with Novo Nordisk (NYSE:NVO) to develop and commercialize oral formulations of the latter’s proprietary GLP-1 receptor agonists for the potential treatment of Type 2 diabetes. Previously conducted clinical trials have confirmed that the Company’s SNAC drug delivery technology allows for the safe and rapid oral absorption of GLP-1.
On 5/21/09, EMIS received a $500,000 milestone payment from MannKind (NASDAQ:MNKD) in connection with that Company’s recent FDA filing and acceptance of a NDA for Afresa as an inhaled, ultra rapid-acting insulin. In early 2008, EMIS sold the rights to certain drug delivery patents to MNKD for an initial payment of $1.5M, and an additional payment of $500,000 remains to be paid to EMIS no later than 10/5/10.
In early May, EMIS reported 1Q09 financial results, which included a net loss of $5.1M and an operating loss of $4.7M compared to a net loss of $3.9M and an operating loss of $6.5M in the year-ago periods. Total operating expenses during 1Q09 were $4.7M versus $6.6M in the year-ago period. At the end of 1Q09, EMIS reported a cash/restricted cash balance of $4.2M, with sufficient capital resources through August 2009 as the Company evaluates both non-dilutive and traditional financing options. Additionally, EMIS achieved a key milestone as part of its cost cutting initiatives with a goal of reducing the Company’s cash burn rate to a level of $7-8M per year.
Another important milestone achieved in early May occurred when the Company was informed by an independent expert panel of scientists that its SNAC carrier was provisionally designated as Generally Recognized as Safe (GRAS) for its intended application in combination with nutrients added to food and dietary supplements. Following a comprehensive evaluation of research and toxicology data, Emisphere’s SNAC was found to be safe at a dosage up to 250 mg per day when used in combination with nutrients to improve their dietary availability.
Achieving final GRAS status will allow EMIS to bypass the FDA as it seeks to commercialize its drug delivery technology to improve the oral absorption of vitamins and other nutritional supplements, such as <font> the Company’s first target – vitamin B12 </font> . EMIS expects to achieve final GRAS status following the publication of two peer reviewed papers describing the toxicology of SNAC, currently scheduled for July/August in the International Journal of Toxicology .
A pharmacokinetic study conducted by EMIS demonstrated that mean vitamin B12 peak blood levels were more than 10X higher for the Eligen B12 5mg formulation compared to a 5mg commercial formulation. In addition, the Eligen formulation was absorbed much quicker as it reached a peak concentration in just 30 minutes versus 6.8 hours for the standard commercial formulation. The overall absorption of B12 was increased by about 240% for the Eligen formulation compared to the standard formulation.
On 4/1/09, Par Pharma (NYSE:PRX) announced that its wholly-owned subsidiary focused on the development of proprietary drug products, Strativa Pharma, acquired the global rights to Nascobal (Cyanocobalamin) Nasal Spray from QOL Medical, LLC. Nascobal Nasal Spray is an FDA approved prescription vitamin B12 supplement indicated to treat vitamin B12 deficiency, and the product represents the first and only once-weekly, self-administered alternative to B12 injections. Strativa Pharma paid $54.5M for the worldwide rights to Nascobal, which equates to nearly 7X the $8M in sales for the product during 2008.
Based on the PRX acquisition, EMIS would be undervalued at its current market cap around $35M based on the potential for an orally available, high-dose B12 product only. A prescription strength B12 formulation that could be taken by mouth would quickly become the market leader as patients would prefer this route to an injection or a squirt up the nose. Other near-term opportunities are possible for poorly absorbed and widely used mineral supplements such as iron.
Of course, EMIS has more than just the near-term opportunity for improved oral delivery of vitamins and nutritional supplements with three ongoing Phase 3 trials for oral calcitonin funded and being conducted by Novartis for the treatment of conditions with major commercial potential in osteoporosis and osteoarthritis. In addition, there is minimal risk of failure or toxicity in the trials since the effects of calcitonin are well characterized and EMIS is simply improving upon the delivery of the drug.
Outstanding issues weighing on the share price include the obvious need for some type of funding or financing by August, submitting additional information by 6/26/09 to maintain the Company’s NASDAQ listing, two outstanding notes, and litigation related to the proprietary technology for the oral administration of vitamin B12 against a former consultant/employee of EMIS. In February 2009, the defendants filed a countersuit against EMIS and the Company believes the counterclaims are without merit and plans to further litigate the matter.
Two outstanding notes payable include a $12.1M Novartis Note which matures on 12/1/09 and currently bears interest at a rate of 7%. EMIS may convert the Novartis Note at any time prior to maturity into a number of shares of its common stock equal to the principal, accrued, and unpaid interest to be converted divided by the then market price of our common stock, provided certain conditions are met. At the end of 1Q09, a portion of the Novartis Note was convertible into 7.54M shares of EMIS common stock.
Conditions affecting this note include that the number of shares issued to Novartis, when issued, does not exceed 19.9% of the total shares of the Company’s common stock outstanding, that at the time of such conversion no event of default under the Note has occurred and is continuing, and that there is either an effective shelf registration statement in effect covering the resale of the shares issued in connection with such conversion or the shares may be resold by Novartis pursuant to SEC Rule 144.
EMIS also has $18.85M in outstanding MHR Convertible Notes. The Convertible Notes are due on 9/26/12 and bear interest at 11% and are secured by a first priority lien in favor of MHR Institutional Partners on substantially all of the Company’s assets. Interest is payable in the form of additional Convertible Notes issued monthly through March 31, 2007 and then semi-annually beginning June 30, 2008, rather than in cash and we have the right to call the Convertible Notes after September 26, 2010 if certain conditions are satisfied.
Further the Convertible Notes provide MHR with the right to require redemption in the event of a change in control, as defined, prior to September 26, 2009. Such required redemption would be at 102% and 101% of the then outstanding principal and interest in the years through September 26, 2008 and 2009, respectively. The Convertible Notes are convertible, at the sole discretion of MHR or any assignee thereof through September 25, 2010, into shares of our common stock at a price per share of $3.78. At March 31, 2009, the Convertible Notes were convertible into 5.5M shares of EMIS common stock.
Despite the issues outlined above which are weighing on the current stock price, EMIS has a promising drug delivery with little in the way of pipeline risk for its Phase 3 oral calcitonin clinical trials since they involve the improved oral delivery of an already used hormone. In addition, the PRX acquisition at 7X sales ($54.5M) for a B12 nasal spray product is similar to the current enterprise value for EMIS ($60M). EMIS should be viewed as a call option trade at its current stock price just north of $1/share, with the potential for multi-bagger gains if the risk factors outlined above are resolved successfully.
Also wenn die Genie´s von "Hot STock" die Aktie bei über 2$ zum Kauf empfehlen dann ist es sicherlich nicht verkehrt unter 1$ einzusteigen, denn es hat sich eigentlich nichts verändert im gegenteil bisher gabs nur gute News !
http://www.finanzen.net/analyse/Emisphere_Technologies_sofor…
Emisphere Technologies sofort kaufen
Endingen (aktiencheck.de AG) - Die Experten von "Hot Stocks Investor" raten, die Aktie von Emisphere Technologies (ISIN US2913451066/ WKN 882963) sofort zu kaufen.
Der Biotech-Wert habe seit Mitte um mehr als 100% an Wert zugelegt. So sei Mitte Juni eine Partnerschaft mit Novo Nordisc bekannt gegeben worden, wobei es um die Nutzung der Technologieplattform von Emisphere Technologies zur Herstellung eines oral zu verabreichenden Diabetesmittel gehe. Nach Angaben von Emisphere Technologies habe dieser Deal einen Wert von mindestens 87 Mio. USD. Des Weiteren seien Anfang Juli Ergebnisse einer unabhängigen Studie publiziert worden, die den Nutzen der Eligen-Technologie von Emisphere Technologies bei der Behandlung von Diabetes bestätige. Und erst vor wenigen Tagen sei eine weitere Erfolgsmeldung im Rahmen der Eligen-Technologie mitgeteilt worden. So sei die Aufnahmebereitschaft des Körpers bei der Verabreichung einer Vitamin B12-Tablette gegenüber einer herkömmlichen Vitamin B12-Tablette um ein Vielfaches gesteigert worden.
Damit sind die Aussichten besser denn je und die Experten von "Hot Stocks Investor" empfehlen, die Emisphere Technologies-Aktie sofort zu kaufen. (Ausgabe 15 vom 11.08.2008) (11.08.2008/ac/a/a) Analyse-Datum: 11.08.2008
http://www.finanzen.net/analyse/Emisphere_Technologies_sofor…
Emisphere Technologies sofort kaufen
Endingen (aktiencheck.de AG) - Die Experten von "Hot Stocks Investor" raten, die Aktie von Emisphere Technologies (ISIN US2913451066/ WKN 882963) sofort zu kaufen.
Der Biotech-Wert habe seit Mitte um mehr als 100% an Wert zugelegt. So sei Mitte Juni eine Partnerschaft mit Novo Nordisc bekannt gegeben worden, wobei es um die Nutzung der Technologieplattform von Emisphere Technologies zur Herstellung eines oral zu verabreichenden Diabetesmittel gehe. Nach Angaben von Emisphere Technologies habe dieser Deal einen Wert von mindestens 87 Mio. USD. Des Weiteren seien Anfang Juli Ergebnisse einer unabhängigen Studie publiziert worden, die den Nutzen der Eligen-Technologie von Emisphere Technologies bei der Behandlung von Diabetes bestätige. Und erst vor wenigen Tagen sei eine weitere Erfolgsmeldung im Rahmen der Eligen-Technologie mitgeteilt worden. So sei die Aufnahmebereitschaft des Körpers bei der Verabreichung einer Vitamin B12-Tablette gegenüber einer herkömmlichen Vitamin B12-Tablette um ein Vielfaches gesteigert worden.
Damit sind die Aussichten besser denn je und die Experten von "Hot Stocks Investor" empfehlen, die Emisphere Technologies-Aktie sofort zu kaufen. (Ausgabe 15 vom 11.08.2008) (11.08.2008/ac/a/a) Analyse-Datum: 11.08.2008
Die Instis haben sich massiv EMIS-Aktien zugelegt unter anderem ist auch Dendreon´s ehemaliger Top-Shareholder BAM Capital dabei !!
Na wenn das keine guten Aussichten sind !
http://www.nasdaq.com/asp/quotes_sec.asp?symbol=EMIS&symbol=…
Na wenn das keine guten Aussichten sind !
http://www.nasdaq.com/asp/quotes_sec.asp?symbol=EMIS&symbol=…
Antwort auf Beitrag Nr.: 37.927.360 von BrauchGeld am 06.09.09 12:36:42Und wenn gehört auf die Genie´s von "Hot STock" würden heute einige mit mehr als 50% in minus stehen ! 
Antwort auf Beitrag Nr.: 37.925.527 von BrauchGeld am 05.09.09 14:07:31Jetzt mal im ernst !
Mit welchen Umsätzen kann bei einer Markteinführung rechnen ?
Emisphere hat 2 Phase III Studien (osteoarthritis und osteoporosis)
Das wäre mal ein wichtiger Anhaltspunkt der einen Einstieg in Erwägung ziehen könnte!
Mit welchen Umsätzen kann bei einer Markteinführung rechnen ?
Emisphere hat 2 Phase III Studien (osteoarthritis und osteoporosis)
Das wäre mal ein wichtiger Anhaltspunkt der einen Einstieg in Erwägung ziehen könnte!
Trading Spotlight
Osteoarthritis ist ein Blockbuster Markt und Osteoporose so ca 300-500 M$ Markt .
Aus der Analyse vom 1.Posting
EMIS has more than just the near-term opportunity for improved oral delivery of vitamins and nutritional supplements with three ongoing Phase 3 trials for oral calcitonin funded and being conducted by Novartis for the treatment of conditions with major commercial potential in osteoporosis and osteoarthritis. In addition, there is minimal risk of failure or toxicity in the trials since the effects of calcitonin are well characterized and EMIS is simply improving upon the delivery of the drug.
-------
Auch die Vitamin B12 tablette das in kürze am Markt erhältlich sein wird hat hohes Potential .
Par Pharma hat z.b. eine Firma nur wegen der Vitamin B12(Nasal Spray) produkt übernommen und dafür fast doppelt soviel bezahlt als EMIS aktuell wert ist .
Based on the PRX acquisition, EMIS would be undervalued at its current market cap around $35M based on the potential for an orally available, high-dose B12 product only. A prescription strength B12 formulation that could be taken by mouth would quickly become the market leader as patients would prefer this route to an injection or a squirt up the nose.
http://www.parpharm.com/media/NR_20090401.jsp
Aus der Analyse vom 1.Posting
EMIS has more than just the near-term opportunity for improved oral delivery of vitamins and nutritional supplements with three ongoing Phase 3 trials for oral calcitonin funded and being conducted by Novartis for the treatment of conditions with major commercial potential in osteoporosis and osteoarthritis. In addition, there is minimal risk of failure or toxicity in the trials since the effects of calcitonin are well characterized and EMIS is simply improving upon the delivery of the drug.
-------
Auch die Vitamin B12 tablette das in kürze am Markt erhältlich sein wird hat hohes Potential .
Par Pharma hat z.b. eine Firma nur wegen der Vitamin B12(Nasal Spray) produkt übernommen und dafür fast doppelt soviel bezahlt als EMIS aktuell wert ist .
Based on the PRX acquisition, EMIS would be undervalued at its current market cap around $35M based on the potential for an orally available, high-dose B12 product only. A prescription strength B12 formulation that could be taken by mouth would quickly become the market leader as patients would prefer this route to an injection or a squirt up the nose.
http://www.parpharm.com/media/NR_20090401.jsp
Ich brauche ein paar Pusher für´s US-Board damit es schneller aufwärts geht ,die Aktie kennen da noch nicht viele !!
Emisphere Technologies to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
Press Release
Source: Emisphere Technologies, Inc.
On Tuesday September 1, 2009, 12:55 pm EDT
Companies:Emisphere Technologies, Inc.
CEDAR KNOLLS, N.J.--(BUSINESS WIRE)--Emisphere Technologies, Inc. (OTC BB: EMIS - News), a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its Eligen® Technology, today announced that President and Chief Executive Officer, Michael V. Novinski, will present at Rodman & Renshaw’s 11th Annual Healthcare Conference at 11:40 AM EDT on Wednesday, September 9, 2009 in the Henry Salon on the 5th Floor of the New York Palace Hotel in New York City.
damit es schneller aufwärts geht ,die Aktie kennen da noch nicht viele !!Emisphere Technologies to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
Press Release
Source: Emisphere Technologies, Inc.
On Tuesday September 1, 2009, 12:55 pm EDT
Companies:Emisphere Technologies, Inc.
CEDAR KNOLLS, N.J.--(BUSINESS WIRE)--Emisphere Technologies, Inc. (OTC BB: EMIS - News), a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its Eligen® Technology, today announced that President and Chief Executive Officer, Michael V. Novinski, will present at Rodman & Renshaw’s 11th Annual Healthcare Conference at 11:40 AM EDT on Wednesday, September 9, 2009 in the Henry Salon on the 5th Floor of the New York Palace Hotel in New York City.
Hier wird es auch bald aufwärts gehen ...
NEWS
Emisphere Technologies Announces Publication in Clinical Pharmacology and Therapeutics of Encouraging Data from an Independent Clinical Study of an Oral Eligen-GLP-1 Formulation on Glucose HomeostasisBusiness Wire(Tue 10:00am)
http://finance.yahoo.com/news/Emisphere-Technologies-bw-2784…
NEWS
Emisphere Technologies Announces Publication in Clinical Pharmacology and Therapeutics of Encouraging Data from an Independent Clinical Study of an Oral Eligen-GLP-1 Formulation on Glucose HomeostasisBusiness Wire(Tue 10:00am)
http://finance.yahoo.com/news/Emisphere-Technologies-bw-2784…
Antwort auf Beitrag Nr.: 37.939.958 von BrauchGeld am 08.09.09 17:15:29Naja heut siehts mal er nicht so aus.
Gute Einstiegschance?
mfg
Gute Einstiegschance?
mfg
Hab nochmal 5000st.zu 80cent zugelegt .Kurs momentan etwas unter druck wegen der KE .
Bald gehts aufwärts ich rieche das
Bald gehts aufwärts ich rieche das
Hab bisher noch keine Zeit gehabt diese Aktie etwas zu pushen ,man sieht am Volumen das die Aktie sich immer noch unterm Radar bewegt !!
Zulassungsantrag für Oral Calcitonin (Osteoarthritis and Osteoporosis) in 2011 geplant !!
Kann mir auch vorstellen das Novartis EMIS übernimmt !!
,man sieht am Volumen das die Aktie sich immer noch unterm Radar bewegt !!Zulassungsantrag für Oral Calcitonin (Osteoarthritis and Osteoporosis) in 2011 geplant !!
Kann mir auch vorstellen das Novartis EMIS übernimmt !!
Hm, geht ja nur noch abwärts des olle Teil
Gab irgend was wichtiges?
mfg
Gab irgend was wichtiges?
mfg
Antwort auf Beitrag Nr.: 38.012.690 von Baam am 18.09.09 19:39:11Wow 4-5 cent ist die Aktie abgestürzt bleib locker gute Zeiten kommen auch auf EMIS zu .
Hatte noch keine Zeit bisher die Aktie in den Boards vorzustellen .
Bald knacken wir den 1$ ...
bleib locker gute Zeiten kommen auch auf EMIS zu .Hatte noch keine Zeit bisher die Aktie in den Boards vorzustellen
.Bald knacken wir den 1$ ...
an für sich keine schlechte sache, nur wird sie in D so gut wie nicht gehandelt.
mfg
mfg
Mmh jo das is nu nicht so prall, danach hatte ich im Moment noch gar nicht geguckt, weil ich auf seeking die ganzen Seiten durch den Übersetzer jagen muss und mir dann was raus kommt irgendwie zusammenpuzzeln muss.
Werd den Wert aber trotzdem mal auf die Watch setzen mal schauen was so geht
Tommi
Werd den Wert aber trotzdem mal auf die Watch setzen mal schauen was so geht
Tommi
Des ist nämlich des einzige was mich im Moment noch weng zum Grübeln bringt.
mfg
mfg
Antwort auf Beitrag Nr.: 38.093.405 von Baam am 01.10.09 11:51:59In Ermangelung andere Alternativen nehm ich das in Kauf, bin aber im Moment noch woanders investiert so das ich mir darüber noch keine Sorgen machen brauch, aber man muss ja auf dem laufendem bleiben.
Die anderen Invests wollen aber auch nicht in die Strümpfe kommen, is alles ein Elend
Tommi
Die anderen Invests wollen aber auch nicht in die Strümpfe kommen, is alles ein Elend
Tommi
Antwort auf Beitrag Nr.: 38.093.405 von Baam am 01.10.09 11:51:59
an für sich keine schlechte sache, nur wird sie in D so gut wie nicht gehandelt.
Sei doch froh das es so ist, wenn es anders wäre würde die Aktie bestimmt nicht mehr so günstig sein ..
Mach es wie der Tierfilmer Malcolm Douglas der "nie durch ausgetretene Pfade" geht die anderen werden dann schon irgendwann folgen ..
Nur unendeckte Perlen haben riesiges Potential ..
an für sich keine schlechte sache, nur wird sie in D so gut wie nicht gehandelt.
Sei doch froh das es so ist, wenn es anders wäre würde die Aktie bestimmt nicht mehr so günstig sein ..Mach es wie der Tierfilmer Malcolm Douglas der "nie durch ausgetretene Pfade" geht die anderen werden dann schon irgendwann folgen ..
Nur unendeckte Perlen haben riesiges Potential ..
Naja mal schauen evtl. leg ich mir paar zu unter 50cent ins depot, sofern ich da welche bekomm.
mfg
mfg
Super nachrichten ..Emis bringt erstes Produkt auf den Markt !!
Klasse Investment ..
http://finance.yahoo.com/news/Emisphere-Technologies-bw-2379…
Klasse Investment ..
http://finance.yahoo.com/news/Emisphere-Technologies-bw-2379…
Nur leider geht es trotzdem nicht voran. 
mfg
mfg
Beide Phase3-Studien mit Novartis laufen nach Plan ...
EMIS ist auch ein möglicher Multibagger ..
http://finance.yahoo.com/news/Emisphere-Technologies-bw-1854…
Emisphere Technologies Reports DMC Recommendation to Proceed with Phase 3 Clinical Trials with Oral Calcitonin for Osteoporosis and Osteoarthritis
http://seekingalpha.com/article/179100-a-window-of-opportuni…
A Window of Opportunity to Buy Emisphere
Die 1 US$-Marke könnte eventuell nächste Woche fallen ...
EMIS ist auch ein möglicher Multibagger ..
http://finance.yahoo.com/news/Emisphere-Technologies-bw-1854…
Emisphere Technologies Reports DMC Recommendation to Proceed with Phase 3 Clinical Trials with Oral Calcitonin for Osteoporosis and Osteoarthritis
http://seekingalpha.com/article/179100-a-window-of-opportuni…
A Window of Opportunity to Buy Emisphere
Die 1 US$-Marke könnte eventuell nächste Woche fallen ...
Sieht aus als würde meine Vohersage eintreffen ...
grüne welle für Emis ..Ich denke neue Highs stehen bevor
http://quote.barchart.com/texpert.asp?sym=emis&code=BSTK
http://quote.barchart.com/texpert.asp?sym=emis&code=BSTK
Die 1$ Mauer wird gleich durchbrochen ...
Antwort auf Beitrag Nr.: 38.651.953 von BrauchGeld am 31.12.09 17:36:13Glückwunsch du "Trüffelschwein" ,
ich wünsche dir alles Gute für 2010, vor allem Gesundheit und weiterhin viel Erfolg bei deinen Ausgrabungen!!!
Grüße!
,ich wünsche dir alles Gute für 2010, vor allem Gesundheit und weiterhin viel Erfolg bei deinen Ausgrabungen!!!
Grüße!
Antwort auf Beitrag Nr.: 38.651.992 von orfmen am 31.12.09 17:50:38Danke mein bester wünsche dir auch alles gute fürs neue Jahr .
Es scheint los zugehen ...
Auch hier bald neue Hochs !!!
Antwort auf Beitrag Nr.: 38.661.065 von BrauchGeld am 04.01.10 15:50:51Partyyyyyyy
Zweites Produkt nähert sich dem Markt .....
KEY PRODUCT AND CORPORATE DEVELOPMENTS
* Oral Eligen® B-12:
o On November 2, 2009, the Company announced that interim data from an ongoing study demonstrated its high-dose oral Eligen® B12 (1000mcg) performed as well as or better than B12 injections in individuals with Vitamin B12 deficiency. Normal levels of serum B12 and active B12 were achieved by 100 percent of those study participants who have currently taken Eligen® B12 (1000mcg) 15 days into the 90-day study when the first blood samples were taken. It is estimated that between 30 and 40 million high dose injections of B12 are given each year in the U.S. alone and over 250 million such injections are given worldwide. Emisphere’s Eligen® B12 product (1000mcg) is planned to be available in 2010.
o On October 8, 2009, the Company announced that it is introducing and launching its first commercially available product, oral Eligen® B12 (100 mcg). Oral Eligen® B12 (100 mcg), has been specifically developed to help improve Vitamin B12 absorption and bioavailability with a patented formulation. Life Extension® will have certain exclusivity in the U.S. for distribution via the internet and also at specialty health food and nutritional retail outlets including; The Vitamin Shoppe, GNC and Vitamin World. Oral Eligen® B12 (100mcg) tablets will be available starting November of this year. Financial terms of the agreement were not disclosed.
* Oral Salmon Calcitonin:
o On October 15, 2009, Emisphere Technologies announced that Novartis and its partner, Nordic Bioscience, issued study results in which twice-daily oral salmon calcitonin using Emisphere’s proprietary Eligen® Drug Delivery Technology significantly suppressed markers of cartilage and bone degradation versus placebo in men and women with osteoarthritis, the most common form of arthritis. The study, a Phase I, placebo-controlled, double-blind, double-dummy, randomized, gender-stratified clinical trial, was conducted on behalf of Emisphere’s partner Novartis Pharma AG by Nordic Bioscience, and published online in the September 2009 issue of Osteoarthritis and Cartilage. Emerging data continue to indicate oral salmon calcitonin in combination with the Company’s absorption-enhancing Eligen® Technology may be a potential therapeutic option for women and men with osteoarthritis, which affects more than 20 million people in the United States.
* Oral PTH:
o On October 20, 2009, Emisphere Technologies announced study results demonstrating that a single dose of the novel oral parathyroid hormone PTH1-34, which utilizes Emisphere’s proprietary Eligen® Drug Delivery Technology and absorption-enhancer carrier molecule 5-CNAC, achieved potentially therapeutically relevant exposure and safety profiles similar to those of the currently available injectable formulation in healthy postmenopausal women. The results of the study, conducted by Emisphere’s partner Novartis Pharma AG, were presented Monday, October 19, 2009 in a poster session at the 73rd Annual Scientific Meeting of the American College of Rheumatology in Philadelphia, PA. The results of this study indicate we may be able to provide women with postmenopausal osteoporosis a more convenient oral option for parathyroid hormone therapy, which is now available only as an injection.
* Oral Glucagon-Like Peptide-1 (GLP-1):
o On September 8, 2009, Emisphere Technologies announced that an article published in the September 2009 issue of Clinical Pharmacology and Therapeutics, describes previously reported findings of an independent clinical study designed to assess the pharmacokinetics, pharmacodynamics (PK/PD) and safety of oral administration of the peptide GLP-1 utilizing Emisphere’s Eligen® carrier technology. The study was conducted at the University Hospital in Basel, Switzerland by Professor Christoph Beglinger, of the Clinical Research Center, Department of Biomedicine Division of Gastroenterology, and Department of Clinical Pharmacology and Toxicology at the hospital. The published data show that the orally administered peptide, when administered with Emisphere’s SNAC® carrier, is rapidly absorbed from the gut, leading to tenfold higher plasma concentrations compared to control. The pharmacodynamic effects were consistent with the known pharmacology of GLP-1, resulting in significantly increased basal insulin release (P< 0.027), and marked effects on glucose levels. The postprandial glucose peak was delayed with GLP-1, suggesting an effect on gastric emptying. No adverse events were reported.
KEY PRODUCT AND CORPORATE DEVELOPMENTS
* Oral Eligen® B-12:
o On November 2, 2009, the Company announced that interim data from an ongoing study demonstrated its high-dose oral Eligen® B12 (1000mcg) performed as well as or better than B12 injections in individuals with Vitamin B12 deficiency. Normal levels of serum B12 and active B12 were achieved by 100 percent of those study participants who have currently taken Eligen® B12 (1000mcg) 15 days into the 90-day study when the first blood samples were taken. It is estimated that between 30 and 40 million high dose injections of B12 are given each year in the U.S. alone and over 250 million such injections are given worldwide. Emisphere’s Eligen® B12 product (1000mcg) is planned to be available in 2010.
o On October 8, 2009, the Company announced that it is introducing and launching its first commercially available product, oral Eligen® B12 (100 mcg). Oral Eligen® B12 (100 mcg), has been specifically developed to help improve Vitamin B12 absorption and bioavailability with a patented formulation. Life Extension® will have certain exclusivity in the U.S. for distribution via the internet and also at specialty health food and nutritional retail outlets including; The Vitamin Shoppe, GNC and Vitamin World. Oral Eligen® B12 (100mcg) tablets will be available starting November of this year. Financial terms of the agreement were not disclosed.
* Oral Salmon Calcitonin:
o On October 15, 2009, Emisphere Technologies announced that Novartis and its partner, Nordic Bioscience, issued study results in which twice-daily oral salmon calcitonin using Emisphere’s proprietary Eligen® Drug Delivery Technology significantly suppressed markers of cartilage and bone degradation versus placebo in men and women with osteoarthritis, the most common form of arthritis. The study, a Phase I, placebo-controlled, double-blind, double-dummy, randomized, gender-stratified clinical trial, was conducted on behalf of Emisphere’s partner Novartis Pharma AG by Nordic Bioscience, and published online in the September 2009 issue of Osteoarthritis and Cartilage. Emerging data continue to indicate oral salmon calcitonin in combination with the Company’s absorption-enhancing Eligen® Technology may be a potential therapeutic option for women and men with osteoarthritis, which affects more than 20 million people in the United States.
* Oral PTH:
o On October 20, 2009, Emisphere Technologies announced study results demonstrating that a single dose of the novel oral parathyroid hormone PTH1-34, which utilizes Emisphere’s proprietary Eligen® Drug Delivery Technology and absorption-enhancer carrier molecule 5-CNAC, achieved potentially therapeutically relevant exposure and safety profiles similar to those of the currently available injectable formulation in healthy postmenopausal women. The results of the study, conducted by Emisphere’s partner Novartis Pharma AG, were presented Monday, October 19, 2009 in a poster session at the 73rd Annual Scientific Meeting of the American College of Rheumatology in Philadelphia, PA. The results of this study indicate we may be able to provide women with postmenopausal osteoporosis a more convenient oral option for parathyroid hormone therapy, which is now available only as an injection.
* Oral Glucagon-Like Peptide-1 (GLP-1):
o On September 8, 2009, Emisphere Technologies announced that an article published in the September 2009 issue of Clinical Pharmacology and Therapeutics, describes previously reported findings of an independent clinical study designed to assess the pharmacokinetics, pharmacodynamics (PK/PD) and safety of oral administration of the peptide GLP-1 utilizing Emisphere’s Eligen® carrier technology. The study was conducted at the University Hospital in Basel, Switzerland by Professor Christoph Beglinger, of the Clinical Research Center, Department of Biomedicine Division of Gastroenterology, and Department of Clinical Pharmacology and Toxicology at the hospital. The published data show that the orally administered peptide, when administered with Emisphere’s SNAC® carrier, is rapidly absorbed from the gut, leading to tenfold higher plasma concentrations compared to control. The pharmacodynamic effects were consistent with the known pharmacology of GLP-1, resulting in significantly increased basal insulin release (P< 0.027), and marked effects on glucose levels. The postprandial glucose peak was delayed with GLP-1, suggesting an effect on gastric emptying. No adverse events were reported.
Ich glaube auch hier stehen bald News an das Handelsvolumen ist in den letzten tagen gestiegen ...
Und da sind auch schon die News .....
http://finance.yahoo.com/news/Novo-Nordisk-Starts-Phase-I-bw…
Novo Nordisk Starts Phase I Trial with Long-Acting Oral GLP-1 Analogue
Emisphere earns $2 million milestone payment
http://finance.yahoo.com/news/Novo-Nordisk-Starts-Phase-I-bw…
Novo Nordisk Starts Phase I Trial with Long-Acting Oral GLP-1 Analogue
Emisphere earns $2 million milestone payment
Wer wird sich Emisphere schnappen Novo Nordisk oder Novartis ????
Für beide wäre es billiger als Royalties zu zahlen ...
Für beide wäre es billiger als Royalties zu zahlen ...
http://finance.yahoo.com/news/Emisphere-to-Present-at-12th-b…
auch wenn hier wahrscheinlich eh keiner mehr reinschaut..
auch wenn hier wahrscheinlich eh keiner mehr reinschaut..
Jeden Tag min. 10 % rauf und keiner bemerkt es Still und leise kauft jemand den Laden auf.
Leider bin ich seit Tagen nur Zuschauer und jetzt noch einzusteigen ist mir zu unsicher. Trotzdem Glückwunsch an alle die an die Story geglaubt haben.
Sollte eine der Studien einschlagen kracht es richtig durch die Decke.
Still und leise kauft jemand den Laden auf.Leider bin ich seit Tagen nur Zuschauer und jetzt noch einzusteigen ist mir zu unsicher. Trotzdem Glückwunsch an alle die an die Story geglaubt haben.
Sollte eine der Studien einschlagen kracht es richtig durch die Decke.
ja dann bietet sich doch Heute eine gute Gelegenheit um einzusteigen. Ich bin auch schon seit etwas längerem dabei und wundere mich das hier irgendwie das scheinbar nicht soviele den Kursanstieg der letzten Wochen gemerkt, bzw. kommentiert hat.
knapp 260% seit Jahresanfang, wirkliches Interesse sieht aber anders!Was ist denn hier los?
Antwort auf Beitrag Nr.: 39.363.523 von newhousen am 19.04.10 20:26:27Meine Meinung? Einer kauft den Laden auf bevor Übernahme bekannt gegeben wird oder erfolgreiche Phase 3.
Das Ding erinnert mich an Human Genome.
Habe mir trotzdem nur eine kleine Position gegönnt weil ich dem Braten nicht 100% traue.
Das Ding erinnert mich an Human Genome.
Habe mir trotzdem nur eine kleine Position gegönnt weil ich dem Braten nicht 100% traue.
Press Release Source: Emisphere Technologies, Inc. On Monday May 10, 2010, 9:57 am
CEDAR KNOLLS, N.J., May 10, 2010 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS - News) announced today that management will host a conference call to discuss the Company's financial and operational results for the first quarter of 2010 on Monday, May 17, 2010 at 10:00 AM EDT. A press release will be issued prior to market open.
The live webcast of the conference call can be accessed through the company's web site at: www.emisphere.com. The live conference call dial-in number is: 1-888-819-8033 (United States and Canada) or 1-913-312-0660 (International). In addition, an archive of the webcast can be accessed through the same link and an audio replay of the call will be available beginning at 1:00 PM EDT through midnight on May 31, 2010 by calling 1-888-203-1112 (United States and Canada) or 1-719-457-0820 (International). The conference replay PIN is 6763914.
About Emisphere Technologies, Inc.
Emisphere is a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds, medical foods and dietary supplements using its Eligen(R) Technology. These molecules and compounds could be currently available or in development. Such molecules are usually delivered by injection; in many cases, their benefits are limited due to poor bioavailability, slow on-set of action or variable absorption. The Eligen(R) Technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal. The company's website is: www.emisphere.com.
Safe Harbor Statement Regarding Forward-looking Statements
The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, Emisphere's ability to fund such efforts with or without partners, and other risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 (file no. 000-17758) filed on March 25, 2010.
CEDAR KNOLLS, N.J., May 10, 2010 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS - News) announced today that management will host a conference call to discuss the Company's financial and operational results for the first quarter of 2010 on Monday, May 17, 2010 at 10:00 AM EDT. A press release will be issued prior to market open.
The live webcast of the conference call can be accessed through the company's web site at: www.emisphere.com. The live conference call dial-in number is: 1-888-819-8033 (United States and Canada) or 1-913-312-0660 (International). In addition, an archive of the webcast can be accessed through the same link and an audio replay of the call will be available beginning at 1:00 PM EDT through midnight on May 31, 2010 by calling 1-888-203-1112 (United States and Canada) or 1-719-457-0820 (International). The conference replay PIN is 6763914.
About Emisphere Technologies, Inc.
Emisphere is a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds, medical foods and dietary supplements using its Eligen(R) Technology. These molecules and compounds could be currently available or in development. Such molecules are usually delivered by injection; in many cases, their benefits are limited due to poor bioavailability, slow on-set of action or variable absorption. The Eligen(R) Technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal. The company's website is: www.emisphere.com.
Safe Harbor Statement Regarding Forward-looking Statements
The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, Emisphere's ability to fund such efforts with or without partners, and other risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 (file no. 000-17758) filed on March 25, 2010.
Wegen Nachfrage neu generiert. Allen viel Erfolg!
Novo Nordisk A/S and Emisphere Technologies, Inc. Announce License Agreement to Develop Oral Formulation of Insulin for Diabetes
PR Newswire
PRINCETON, N.J., Dec. 21, 2010
PRINCETON, N.J., Dec. 21, 2010 /PRNewswire/ -- Emisphere Technologies, Inc. (OTC Bulletin Board: EMIS) and Novo Nordisk A/S (NYSE: NVO) today announced that they have entered into an exclusive Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's insulins, which have the potential of treating diabetes, using Emisphere's Eligen® Technology. This is the second license agreement between the two companies. The first agreement for the development of oral formulations of GLP-1 receptor agonists was signed in June 2008 with a potential drug currently in a phase 1 clinical trial.
The insulin agreement includes 57.5 million US dollars in potential product development and sales milestone payments to Emisphere, of which 5 million dollars will be payable upon signing, as well as royalties on sales. Further financial details of the agreement were not made public.
"This is an encouraging agreement on a promising technology for oral administration of proteins. We are delighted to continue working with Emisphere and their Eligen® Technology. It fits very well with Novo Nordisk's strategy within diabetes research," said Peter Kurtzhals, senior vice president, Diabetes Research Unit at Novo Nordisk.
This extended partnership with Novo Nordisk is important for Emisphere for several reasons, said Michael V. Novinski, president and chief executive officer of Emisphere. "To date, our collaboration with Novo Nordisk has been very productive, and today's agreement has the potential to offer significant new solutions to millions of people with diabetes worldwide. Finally, it also serves to further validate our Eligen® Technology."
Emisphere's broad-based drug delivery technology platform, known as the Eligen® Technology, uses proprietary, synthetic chemical compounds, known as Emisphere delivery agents, sometimes called carriers. Emisphere's Eligen® Technology makes it possible to deliver a therapeutic molecule without altering its chemical form or biological integrity.
Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 30,100 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.
Emisphere is a biopharmaceutical company that focuses on the unique and improved delivery of therapeutic molecules or nutritional supplements using its proprietary Eligen® Technology. The Eligen® Technology can be applied to the oral route of administration as well as other delivery pathways such as buccal, rectal, inhalation, intra-vaginal or transdermal. The company's website is www.emisphere.com.
SOURCE Novo Nordisk A/S
PR Newswire
PRINCETON, N.J., Dec. 21, 2010
PRINCETON, N.J., Dec. 21, 2010 /PRNewswire/ -- Emisphere Technologies, Inc. (OTC Bulletin Board: EMIS) and Novo Nordisk A/S (NYSE: NVO) today announced that they have entered into an exclusive Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's insulins, which have the potential of treating diabetes, using Emisphere's Eligen® Technology. This is the second license agreement between the two companies. The first agreement for the development of oral formulations of GLP-1 receptor agonists was signed in June 2008 with a potential drug currently in a phase 1 clinical trial.
The insulin agreement includes 57.5 million US dollars in potential product development and sales milestone payments to Emisphere, of which 5 million dollars will be payable upon signing, as well as royalties on sales. Further financial details of the agreement were not made public.
"This is an encouraging agreement on a promising technology for oral administration of proteins. We are delighted to continue working with Emisphere and their Eligen® Technology. It fits very well with Novo Nordisk's strategy within diabetes research," said Peter Kurtzhals, senior vice president, Diabetes Research Unit at Novo Nordisk.
This extended partnership with Novo Nordisk is important for Emisphere for several reasons, said Michael V. Novinski, president and chief executive officer of Emisphere. "To date, our collaboration with Novo Nordisk has been very productive, and today's agreement has the potential to offer significant new solutions to millions of people with diabetes worldwide. Finally, it also serves to further validate our Eligen® Technology."
Emisphere's broad-based drug delivery technology platform, known as the Eligen® Technology, uses proprietary, synthetic chemical compounds, known as Emisphere delivery agents, sometimes called carriers. Emisphere's Eligen® Technology makes it possible to deliver a therapeutic molecule without altering its chemical form or biological integrity.
Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 30,100 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.
Emisphere is a biopharmaceutical company that focuses on the unique and improved delivery of therapeutic molecules or nutritional supplements using its proprietary Eligen® Technology. The Eligen® Technology can be applied to the oral route of administration as well as other delivery pathways such as buccal, rectal, inhalation, intra-vaginal or transdermal. The company's website is www.emisphere.com.
SOURCE Novo Nordisk A/S
Diabetes-Behandlung in Tablettenform könnte ein Riesending werden! Wäre eine große Erleichterung für die Patienten. Bin gespannt, wie das läuft.
Der Kurs tritt (bis auf einzelne Ausreisser in FFM zum Briefkurs) ziemlich auf der Stelle. Hier wird wohl erst bei den nächsten News etwas passieren (Zahlen und/oder Ergebnisse der Studien).
Emisphere ist unter den "Innovative Leaders". Der Index der Innovative Leaders hat den S&P in der Vergangenheit immer outperformed. EMIS hat dazu wohl nicht beigetragen. Vielleicht klappt's ja in 2011!
http://ir.emisphere.com/releasedetail.cfm?ReleaseID=551242
Und vielliecht klappt es ja im Mai mit einem Award???
http://mdb.com/2010-bright-lights-conference.html
fopc
http://ir.emisphere.com/releasedetail.cfm?ReleaseID=551242
Und vielliecht klappt es ja im Mai mit einem Award???
http://mdb.com/2010-bright-lights-conference.html
fopc
Q-II Zahlen:
http://ir.emisphere.com/releasedetail.cfm?ReleaseID=597914
Cashburn-Ratio 8 Mio. $ pro Jahr
kleiner Gewinn aus Optionsbewertungen wegen des Kursverfalls, aber nichts Liquiditätswirksames.
Ohne Refi-Möglichkeiten ist das Geld wohl im April 2012 alle. Die Chance auf flüssige Mittel wird wohl nicht allzu hoch gesehen.
Trotzdem, der Kurs springt einfach mal hoch. Keine Ahnung warum kann nichts Positives an den Zahlen entdecken.
fopc
http://ir.emisphere.com/releasedetail.cfm?ReleaseID=597914
Cashburn-Ratio 8 Mio. $ pro Jahr
kleiner Gewinn aus Optionsbewertungen wegen des Kursverfalls, aber nichts Liquiditätswirksames.
Ohne Refi-Möglichkeiten ist das Geld wohl im April 2012 alle. Die Chance auf flüssige Mittel wird wohl nicht allzu hoch gesehen.
Trotzdem, der Kurs springt einfach mal hoch. Keine Ahnung warum
kann nichts Positives an den Zahlen entdecken.fopc
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +1,58 | |
| -3,46 | |
| -1,67 | |
| 0,00 | |
| +31,58 | |
| +0,71 | |
| -1,72 | |
| +1,80 | |
| -2,06 | |
| -3,53 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 104 | ||
| 85 | ||
| 50 | ||
| 41 | ||
| 38 | ||
| 37 | ||
| 29 | ||
| 25 | ||
| 24 | ||
| 23 |
